GlassScriptPhysician profile
Lynn S Joffe
NPI 1902947054
$1,874.03
in general payments reported to CMS, 2019-2025
20 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $809 · 2020: $386 · 2021: $45.07 · 2024: $240 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $634.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $448.75 | 2019-2020 | |
| Novo Nordisk INC | $389.59 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $248.02 | 2019-2025 | Airsupra |
| Pfizer INC. | $157.43 | 2019-2025 | |
| Abbvie INC. | $96.84 | 2021-2025 | |
| Glaxosmithkline, LLC. | $79.96 | 2019-2025 | Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $69.33 | 2019-2020 | |
| Lilly USA, LLC | $56.45 | 2024-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $46.65 | 2019-2025 | Capvaxive, Gardasil 9, M-M-R II |
| Astellas Pharma US INC | $46.45 | 2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.96 | 2019-2024 | Xifaxan, Trulance |
| Shire North American Group INC | $39.74 | 2019 | |
| Therapeuticsmd, INC. | $32.63 | 2019-2020 | |
| Ibsa Pharma INC. | $30.80 | 2019 | |
| Sanofi Pasteur INC. | $20.24 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $19.32 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.83 | 2024 | Quviviq |
| Nevro Corp. | $13.68 | 2019 | |
| Boston Scientific Corporation | $12.53 | 2019 | |
| Ironwood Pharmaceuticals, INC | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Joffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.